Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $3,221,253,000 | reported | |
| FY 2024 | 2024-12-31 | $2,853,915,000 | reported | |
| FY 2023 | 2023-12-31 | $2,419,226,000 | reported | |
| FY 2022 | 2022-12-31 | $2,096,039,000 | reported | |
| FY 2021 | 2021-12-31 | $1,846,275,000 | reported | |
| FY 2020 | 2020-12-31 | $1,860,455,000 | reported | |
| FY 2019 | 2019-12-31 | $1,704,048,000 | reported | |
| FY 2018 | 2018-12-31 | $1,491,212,000 | reported | |
| FY 2017 | 2017-12-31 | $1,313,646,000 | reported | |
| FY 2016 | 2016-12-31 | $1,116,854,000 | reported | |
| FY 2015 | 2015-12-31 | $889,895,000 | reported | |
| FY 2014 | 2014-12-31 | $749,284,000 revised | reported |
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
Twelve months to Sep 30, 2026 · derived
BioMarin Pharmaceutical Inc is the 23rd largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
Latest filing Nov 18, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2022 | — | $0.00 | $0.00 | — | 186.53M sh | +1.4% | 0.0% |
| FY2021 | — | $0.00 | $0.00 | — | 184.03M sh | +1.2% | 0.0% |
| FY2020 | — | $50.00M | $50.00M | — | 181.83M sh | +1.1% | — |
| FY2019 | — | $0.00 | $0.00 | — | 179.93M sh | +0.9% | — |
| FY2018 | — | $0.00 | $0.00 | — | 178.37M sh | +1.3% | — |
567 managers · Quarter ended Sep 30, 2026All holders ›
77BioMarin Reports Third Quarter 2026 Financial and Operating Results